GLS and cancer: Here, using immunodeficient and immunocompetent orthotopic murine cancer models, we demonstrate that DRP-104, a broad-acting glutamine antagonist, is efficacious against KEAP1 mutant tumors by a mechanism distinct from GLS1-selective inhibitors, such as CB-839.